LUGANO topline data on track for mid-2026, with LUCIA readout to follow shortly after – – Continued favorable safety profile observed in masked ...

Wet age-related macular degeneration (AMD) is caused by abnormal blood vessels damaging the macula in your eye, which can lead to central vision loss and difficulty seeing details or colors.

Q1 2026 Management view "The start of 2026 for EyePoint was marked by a strong quarter of consistent execution as we approach a pivotal inflection point for our lead program, DURAVYU," said (President ...

Wet age-related macular degeneration advances much more rapidly than the dry form, potentially causing significant vision decline within days to weeks without treatment. Anti-VEGF injections ...

A single injection of the tyrosine kinase inhibitor hydrogel has demonstrated superiority to aflibercept 2 mg in maintaining visual acuity and providing higher rescue-free rates through 1 year in ...

—A new analysis took a 2-prong approach to assessing risk factors for wet age-related macular degeneration: a systematic review of the literature, coupled with a study of decades’ worth of data from ...

Add Yahoo as a preferred source to see more of our stories on Google. Current treatments sometimes fail to help people with "wet" age-related macular degeneration -- and researchers now think they ...

Please provide your email address to receive an email when new articles are posted on . In AVONELLE-X, PULSAR and Portal, patients maintained visual acuity and central subfield thickness. No safety ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. EYP-1901 demonstrated noninferior change in best ...

EyePoint Pharmaceuticals’ investigational therapy for wet age-related macular degeneration (wet AMD) was effective in a Phase 2 trial, the company announced Monday. The announcement was welcome news ...